NCT00455975

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 119 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.

Detailed description

Bevacizumab is considered a targeted drug. Targeted drugs act on specific receptors on a cell. Bevacizumab blocks receptors that help cancer cells develop blood supplies so that the cancer can grow. These specific receptors are found in greater numbers in kidney cancer. In that regard bevacizumab will be tested in 2 doses that are higher than non-kidney cancer treatments with bevacizumab. One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks. A total of 75 patients will be treated with this dose. If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly.

Conditions

• Renal Cancer
• Kidney Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab

Timeline

• Start date: 2007-02-01
• Primary completion: 2013-07-01
• Completion: 2013-09-01
• First posted: 2007-04-04
• Last updated: 2014-12-22
• Results posted: 2014-12-22

Locations

13 sites across 1 country: United States